Mn doping of group-IV semiconductors (Si/Ge) is achieved by embedding nanostructured Mn-layers in group-IV matrix. The Mn-nanostructures are monoatomic Mn-wires or Mn-clusters and capped with an amorphous Si or Ge layer. The precise fabrication of δ-doped Mn-layers is combined with element-specific detection of the magnetic signature with x-ray magnetic circular dichroism. The largest moment (2.5 μB/Mn) is measured for Mn-wires with ionic bonding character and a-Ge overlayer cap; a-Si capping reduces the moment due to variations of bonding in agreement with theoretical predictions. The moments in δ-doped layers dominated by clusters is quenched with an antiferromagnetic component from Mn-Mn bonding.

Py/FeMn/Cu(001) and Py/FeMn/Ni/Cu(001) films were grown and studied as a function of both the FeMn and the Ni thicknesses using rotating magneto-optic Kerr effect and x-ray magnetic circular dichroism. For Py/FeMn/Cu(001), we find that the FeMn antiferromagnetic order switches the sign of the Py fourfold magnetic anisotropy but has little effect on the step-induced uniaxial magnetic anisotropy. For Py/FeMn/Ni/Cu(001), we find that out-of-plane Ni magnetization has little effect on the Py magnetic anisotropy, but in-plane Ni magnetization enhances the Py magnetic anisotropy in the region just above antiferromagnetic transition thickness. The underlying mechanism could be attributed to the FeMn 3Q spin structure. © 2013 American Physical Society.

Amorphous FexSi1-x thin films exhibit a striking enhancement in magnetization compared to crystalline films with the same composition (0.45 < x < 0.75), and xray magnetic circular dichroism reveals an enhancement in both spin and orbital moments in the amorphous films. Density functional theory (DFT) calculations reproduce this enhanced magnetization and also show a relatively large spinpolarization at the Fermi energy, also seen experimentally in Andreev reflection. Theory and experiment show that the amorphous materials have a decreased number of nearest neighbors and reduced number density relative to the crystalline samples of the same composition; the associated decrease in Fe-Si neighbors reduces the hybridization of Fe orbitals, leading to the enhanced moment.

We study the coexistence of strain- and charge-mediated magnetoelectric coupling in a cobalt (0-7 nm) wedge on ferroelectric (011)-oriented [Pb(Mg1/3/Nb2/3)O3]0.68-[PbTiO3]0.32 using surface-sensitive x-ray magnetic circular dichroism spectroscopy at the Co L3,2 edges. Three distinct electric field driven remanent magnetization states can be set in the Co film at room temperature. Ab initio density functional theory calculations unravel the relative contributions of both strain and charge to the observed magnetic anisotropy changes illustrating magnetoelectroelastic coupling at artificial multiferroic interfaces.

Unlike other 3d transition metal monoxides (MnO, FeO, CoO, and NiO), CuO is found in a low-symmetry distorted monoclinic structure rather than the rocksalt structure. We report here of the growth of ultrathin CuO films on SrTiO3 substrates; scanning transmission electron microscopy was used to show the stabilization of a tetragonal rocksalt structure with an elongated c-axis such that and the Cu-O-Cu bond angle , pointing to metastable six-fold coordinated Cu. X-ray absorption spectroscopy demonstrates that the hole at the Cu site for the CuO is localized in orbital unlike the well-studied monoclinic CuO phase. The experimental confirmation of the tetragonal structure of CuO opens up new avenues to explore electronic and magnetic properties of six-fold coordinated Cu. © Copyright EPLA, 2014.

We use polarization- and temperature-dependent x-ray absorption spectroscopy, in combination with photoelectron microscopy, x-ray diffraction, and electronic transport measurements, to study the driving force behind the insulator-metal transition in VO_{2}. We show that both the collapse of the insulating gap and the concomitant change in crystal symmetry in homogeneously strained single-crystalline VO_{2} films are preceded by the purely electronic softening of Coulomb correlations within V-V singlet dimers. This process starts 7 K (±0.3  K) below the transition temperature, as conventionally defined by electronic transport and x-ray diffraction measurements, and sets the energy scale for driving the near-room-temperature insulator-metal transition in this technologically promising material.

p53 activation is a primary mechanism underlying pathological responses to DNA damaging agents such as chemotherapy and radiotherapy. Our recent animal studies showed that low dose arsenic (LDA)-induced transient p53 inhibition selectively protected normal tissues from chemotherapy-induced toxicity. Study objectives were to: 1) define the lowest safe dose of arsenic trioxide that transiently blocks p53 activation in patients and 2) assess the potential of LDA to decrease hematological toxicity from chemotherapy. Patients scheduled to receive minimum 4 cycles of myelosuppressive chemotherapy were eligible. For objective 1, dose escalation of LDA started at 0.005 mg/kg/day for 3 days. This dose satisfied objective 1 and was administered before chemotherapy cycles 2, 4, and 6 for objective 2. p53 level in peripheral lymphocytes was measured on day 1 of each cycle by ELISA assay. Chemotherapy cycles 1, 3, and 5 served as the baseline for the subsequent cycles of 2, 4, and 6 respectively. If p53 level for the subsequent cycle was lower (or higher) than the baseline cycle, p53 was defined as "suppressed" (or "activated") for the pair of cycles. Repeated measures linear models of CBC in terms of day, cycle, p53 activity and interaction terms were used. Twenty-six patients treated with 3 week cycle regimens form the base of analyses. The mean white blood cell, hemoglobin and absolute neutrophil counts were significantly higher in the "suppressed" relative to the "activated" group. These data support the proof of principle that suppression of p53 could lead to protection of bone marrow in patients receiving chemotherapy.This trial is registered in ClinicalTrials.gov. Identifier: NCT01428128.